GlassScriptPhysician profile
Muhammad Khokhar
NPI 1033145586
$4,544.93
in general payments reported to CMS, 2019-2025
28 companies · $2,033 in 2025
The $2,033 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.62 · 2021: $132 · 2022: $64.26 · 2023: $276 · 2024: $1,962 · 2025: $2,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,193 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,192.69 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,021.26 | 2023-2025 | Vemlidy, Livdelzi |
| Abbvie INC. | $761.55 | 2019-2025 | |
| Janssen Biotech, INC. | $447.66 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.74 | 2019-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $221.98 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $216.15 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $208.98 | 2024-2025 | Entyvio |
| Pfizer INC. | $183.86 | 2023-2025 | |
| Braintree Laboratories, INC. | $153.67 | 2023-2025 | Suflave, Sutab |
| Novo Nordisk INC | $140.50 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $137.99 | 2024-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $121.00 | 2024-2025 | Resmetirom, Rezdiffra |
| Qol Medical, LLC | $105.89 | 2025 | Sucraid |
| Daiichi Sankyo INC. | $76.46 | 2023-2024 | Injectafer |
| Janssen Scientific Affairs, LLC | $64.26 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $51.61 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $48.66 | 2024-2025 | Voquezna |
| Genentech USA, INC. | $47.77 | 2025 | Polivy |
| Celgene Corporation | $41.07 | 2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $36.96 | 2024 | |
| Organon LLC | $30.72 | 2025 | Hadlima |
| Exact Sciences Corporation | $27.96 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $26.11 | 2024 | Dificid |
| Genzyme Corporation | $25.00 | 2025 | |
| Alnylam Pharmaceuticals INC. | $24.91 | 2025 | Givlaari |
| Beone Medicines USA, INC. | $21.66 | 2025 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $20.00 | 2025 | Monoferric |
| Glaxosmithkline, LLC. | $19.55 | 2025 | Jemperli, Zejula |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khokhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.